comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 19:15:52 - browse：2624

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： How state and local governments are sidelining science

focus

WSS

As the dark side of IVF slowly comes into focus, even more transparency is needed

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

CDC: Cases of alpha

Timeline: Special counsel's probe into Trump's handling of classified documents

The mammogram wars are not over

focus

comprehensive

leisure time

Medical records are filled with copy

First transplant of an entire human eye performed

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The mammogram wars are not over

The high cost of giving birth even with insurance

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Walensky prepares to leave CDC — and Congress — behind

Behind warning on Apellis’s eye drug lies a conflict of interest

Virginia high school admissions case could be legal follow

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

entertainment

Timeline: Special counsel's probe into Trump's handling of classified documents

Study suggests Covid rebound is far more common with Paxlovid than without

First transplant of an entire human eye performed

Hospitals, health systems can help patients avoid medical debt

Timeline: Special counsel's probe into Trump's handling of classified documents

Today's health inequities arise from racist U.S. history, say experts

focus

hotspot

focus

focus